Characterization of human erythrocytes as potential carrier for pravas-tatin: An in vitro study

International Journal of Medical Sciences

Volumn 8, Issue 3, 2011, Pages 222-230

  Harisa, Gamal El din I ^a   Ibrahim, Mohamed F ^a   Alanazi, Fars K ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Drug delivery; Erythrocytes; Osmotic fragility; Pravastatin

Indexed keywords

DRUG CARRIER; GLUTARALDEHYDE; PHOSPHATE BUFFERED SALINE; PRAVASTATIN;

ARTICLE; CELL ENCAPSULATION; CELL FUNCTION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ERYTHROCYTE; ERYTHROCYTE FRAGILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; TEMPERATURE SENSITIVITY; VALIDATION PROCESS;

EID: 79955535551     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8.222     Document Type: Article

References (40)

1. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002; 87(4):1451-1458.
2. Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Life Sciences. 1999;65(13):1329-1337.
3. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmaco-kinet. 2002; 41(5):343-370.
4. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39:397-412.
5. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2004; 57(2):181-187.
6. Koitabashi Y, Kumai T, Matsumoto N, Watanabe M, Sekine S, Yanagida Y, Kobayashi S. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibi-tor, in rats and healthy human subjects. Life Sciences. 2006; 78(24):2852-2859.
7. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006; 151(2):273-281.
8. Oda S, Nagahama R, Nakano K, Matoba T, Kubo M, Sunagawa K, Tominaga R, Egashira K. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. JVS. 2010;52(2):412-420.
9. Kang B. Development of self-microemulsifying drug delivery sys-tems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm. 2004; 274(1-2):65-73.
10. Charman WN, Chan HK, Finnin BC, Charman SA. Drug Delivery: A Key Factor in Realising the Full Therapeutic Potential of Drugs. Drug Dev Res. 1999;46:316-327.
11. Margulis-Goshen K, Magdassi S. Formation of simvastatin nano-particles from microemulsion. Nanomedicine: NBM. 2009; 5(3):274-281.
12. Gupta A, Mishra AK, Bansal P, Kumar S, Gupta V, Singh R, Kalyan GS. Cell Based Drug Delivery System Through Resealed Erythro-cyte- A Review. Int J Pharm. 2010; 2(1):23-30.
13. Shavi GV, Doijad RC, Deshpande PB, Manvi FV, Meka SR, Udupa N, Omprakash R, Dhirendra K. Erythrocytes as carrier for predni-solone: in vitro and in vivo evaluation. Pak J Pharm Sci. 2010; 23(2):194-200.
14. Gothoskar AV. Resealed Erythrocytes:A Review. J Pharm Technol. 2004;:140-158.
15. Hamidi M, Zarrin A, Foroozesh M, Zarei N, Mohammadisamani S. Preparation and in vitro evaluation of carrier erythrocytes for RES-targeted delivery of interferon-alpha 2b. Int J Pharm. 2007; 341(1-2):125-133.
16. Gopal VS, Ranjith Kumar AN. Usha NA, Karthik A, Udupa N. Effective drug targeting by Erythrocytes as Carrier Systems. Curr Trends Biotechnol Pharm. 2007;1(1):18-33.
17. Davoust J, Gruenberg J, Howell KE. Two threshold values of low pH block endocytosis at different stages. EMBO J. 1987; 6(12):3601-3609.
18. Patel RP. An Overview of Resealed Erythrocyte Drug Delivery. J Pharm Res. 2009; 2(6): 1008-1012.
19. Hamidi M, Tajerzadeh H. Carrier erythrocytes: an overview. Drug Deliv. 2003;10(1):9-20.
20. Pierigè F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Deliv Rev. 2008; 60(2):286-295.
21. Rossi L, Serafini S, Pierige F, Antonelli A, Cerasi A, Fraternale A, Chiarantini L, Magnani M. Erythrocyte-based drug delivery. Expert Opin Drug Deliv. 2005; 2(2):311-22.
22. Millan C, Zarzuelo Castaneda A, Sayalero Marinero ML, Lanao JM. Drug, enzyme and peptide delivery using erythrocytes as carriers. J Controlled Release. 2004; 95(1):27-49.
23. Gutierrez Millan C, Zarzuelo Castaneda A, Sayalero Marinero ML, Lanao JM. Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis. Blood Cells Mol Dis. 2004; 33(2):132-140.
24. Gutierrez Millan C, Bax BE, Castaneda AZ, Marinero ML, Lanao JM. In vitro studies of amikacin-loaded human carrier erythrocytes. Transl Res. 2008; 152(2):59-66.
25. Hamidi M, Zarei N, Zarrin AH, Mohammadi-Samani S. Preparation and in vitro characterization of carrier erythrocytes for vaccine de-livery. Int J Pharm. 2007; 338(1-2):70-78.
26. Kraus A, Roth HP, Kirchgessner M. Supplementation with vitamin C, vitamin E or beta-carotene influences osmotic fragility and oxi-dative damage of erythrocytes of zinc-deficient rats. J Nutr. 1997; 127(7):1290-1296.
27. Solomon M, Wofford J, Johnson C, Regan D, Creer MH. Factors influencing cord blood viability assessment before cryopreserva-tion. Transfusion. 2010; 50(4):820-830.
28. Schrier SL, Junga I, Ma L. Studies on the effect of vanadate on en-docytosis and shape changes in human red blood cells and ghosts. Blood. 1986; 68:1008-1014.
29. Schrier SL, Junga I, Ma L. Requirements of drug-induced endocy-tosis by intact human erythrocytes. Blood Cells. 1978; 4:339-359.
30. Matovcik LM, Junga IG, Schrier SL. Drug-induced endocytosis of neonatal erythrocytes. Blood. 1985; 65:1056-1063.
31. Hamidi M, Zarrin AH, Foroozesh M, Zarei N, Mohammadi-Samani S. Preparation and in vitro evaluation of carrier erythrocytes for RES-targeted delivery of interferon-alpha 2b. Int J Pharm. 2007; 341(1-2):125-133.
32. Bossa F, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Annese V. Erythro-cytes-mediated delivery of low doses of dexamethasone revert steroid-dependency in ulcerative colitis. a double-blind, sham-controlled study. Digest Liver Dis. 2008; 40(1):S44-S44.
33. Talwar N, Jain NK. Erythrocyte based delivery system of prima-quine: in vitro characterization. J Microencapsul. 1992; 9(3):357-364.
34. Hamidi M, Tajerzadeh H, Dehpour AR, Rouini MR, Ejtemaee-Mehr S. In vitro characterization of human intact erythrocytes loaded by enalaprilat. Drug Deliv. 2001; 8(4):223-230.
35. Alanazi F. Pravastatin provides antioxidant activity and protection of erythrocytes loaded Primaquine. Int J Med Sci. 2010; 7(6):358-365.
36. Pierige F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Deliv Rev. 2008; 60(2):286-295.
37. Jain S, Jain NK. Engineered Erythrocytes As A Drug Delivery Sys-tem. Indian J Pharm Sci. 1997; 59(6): 275-281.
38. Erchler HG, Rameis H, Bauer K, Korn A, Bacher S, Gasic S. Survival of gentamicin-loaded carrier erythrocytes in healthy human volun-teers. Eur J Clin Invest. 1986; 16(1):39-42.
39. Hamidi M, Tajerzadeh H, Dehpour AR, Ejtemaee-Mehr S. Inhibition of serum angiotensin-converting enzyme in rabbits after intrave-nous administration of enalaprilat-loaded intact erythrocytes. J Pharm Pharmacol. 2001; 53(9):1281-1286.
40. Erchler HG, Gasic S, Bauer K, Korn A, Bacher S. In vivo clearance of antibody-sensitized human drug carrier erythrocytes. Clin Phar-macol Ther. 1986; 40(3):300-303.